Molecular mechanism of empagliflozin cardioprotection in 5-fluorouracil (5-FU)-induced cardiotoxicity via modulation of SGLT2 and TNFα/TLR/NF-κB signaling …
MMM Refaie, S Shehata, M El-Hussieny… - Toxicological …, 2024 - Springer
One of the commoly used chemotherapeutic agents is 5-Fluorouracil (5-FU). Unfortunately,
the clinical administration of 5-FU is complicated with serious cardiotoxic effects and the safe …
the clinical administration of 5-FU is complicated with serious cardiotoxic effects and the safe …
Cardioprotective Effect of Empagliflozin in Rats with Isoproterenol-Induced Myocardial Infarction: Evaluation of Lipid Profile, Oxidative Stress, Inflammation, DNA …
The antidiabetic drug empagliflozin is reported to have many cardioprotective effects.
However, no studies have investigated the protective effects of empagliflozin (EMPA) in …
However, no studies have investigated the protective effects of empagliflozin (EMPA) in …
[PDF][PDF] Potential Role of Empagliflozin to Ameliorate Doxorubicin Induced Cardiotoxicity in Male Rats
RN Albakaa, FA Rizij, RMA Hassan - J. Med. Chem. Sci, 2023 - researchgate.net
Empagliflozin (EMPA), a selective inhibitor of the sodium-glucose co-transporter 2, is
especially effective at regulating blood-sugar levels [1]. Compared to conventional optimum …
especially effective at regulating blood-sugar levels [1]. Compared to conventional optimum …
Empagliflozin attenuates doxorubicin-induced cardiotoxicity by activating AMPK/SIRT-1/PGC-1α-mediated mitochondrial biogenesis
M Chen - Toxicology Research, 2023 - academic.oup.com
We aimed to probe the functions and possible mechanisms of empagliflozin in doxorubicin
(Dox)-caused cardiotoxicity. First, a cardiotoxicity rat model was built by continuously …
(Dox)-caused cardiotoxicity. First, a cardiotoxicity rat model was built by continuously …
Empagliflozin significantly prevents the doxorubicin-induced acute cardiotoxicity via non-antioxidant pathways
VÖ Barış, AB Dinçsoy, E Gedikli, S Zırh… - Cardiovascular …, 2021 - Springer
Empagliflozin (EMPA) is a SGLT-2 inhibitor that has positive effects on cardiovascular
outcomes. In this study, we aim to evaluate the possible protective effects of EMPA against …
outcomes. In this study, we aim to evaluate the possible protective effects of EMPA against …
Role of hypoxia inducible factor/vascular endothelial growth factor/endothelial nitric oxide synthase signaling pathway in mediating the cardioprotective effect of …
MM Mahmoud Refaie, AMA Bayoumi… - Human & …, 2023 - journals.sagepub.com
Background Cyclophosphamide (CP) is a commonly used chemotherapeutic and
immunosuppressive alkylating agent. However, cardiac adverse effects of CP interfere with …
immunosuppressive alkylating agent. However, cardiac adverse effects of CP interfere with …
Empagliflozin attenuates doxorubicin-induced cardiotoxicity
VÖ Barış, AB Dinçsoy, E Gedikli, S Zırh… - Toxicology …, 2023 - academic.oup.com
In previous issues of the journal, we have just read with great interest the paper by chen
entitled “Empagliflozin attenuates doxorubicin-induced cardiotoxicity by activating …
entitled “Empagliflozin attenuates doxorubicin-induced cardiotoxicity by activating …
The SGLT-2 inhibitor empagliflozin improves myocardial strain, reduces cardiac fibrosis and pro-inflammatory cytokines in non-diabetic mice treated with doxorubicin
V Quagliariello, M De Laurentiis, D Rea… - Cardiovascular …, 2021 - Springer
Background Empagliflozin (EMPA), a selective inhibitor of the sodium glucose co-transporter
2, reduced the risk of hospitalization for heart failure and cardiovascular death in type 2 …
2, reduced the risk of hospitalization for heart failure and cardiovascular death in type 2 …
Empagliflozin alleviates myocardial I/R injury and cardiomyocyte apoptosis via inhibiting ER stress-induced autophagy and the PERK/ATF4/Beclin1 pathway
CC Wang, Y Li, XQ Qian, H Zhao, D Wang… - Journal of Drug …, 2022 - Taylor & Francis
To explore the mechanisms underlying the specific inhibitor targeting SGLT-2 empagliflozin
in alleviating myocardial ischaemia–reperfusion (I/R) injury. A mouse model of I/R injury and …
in alleviating myocardial ischaemia–reperfusion (I/R) injury. A mouse model of I/R injury and …
Empagliflozin prohibits high-fructose diet-induced cardiac dysfunction in rats via attenuation of mitochondria-driven oxidative stress
SGLT2 inhibitors show promising cardio-protection in the diabetic populace. However, the
defending effect of SGLT2 inhibition in diabetes-associated cardiac complications and the …
defending effect of SGLT2 inhibition in diabetes-associated cardiac complications and the …